2022 World Conference on Lung Cancer (ePosters)-EP05.02-011. Phase II Trial of Neoadjuvant Tislelizumab with Chemotherapy for Resectable Stage IIB-III Non-small Cell Lung Cancer

EP05.02-011. Phase II Trial of Neoadjuvant Tislelizumab with Chemotherapy for Resectable Stage IIB-III Non-small Cell Lung Cancer

Back to course

Pdf Summary

A study was conducted to evaluate the safety and efficacy of preoperative treatment with tislelizumab combined with chemotherapy in stage IIB-III non-small cell lung cancer (NSCLC) in an Asian population. Tislelizumab is a monoclonal antibody that targets PD-1 and has shown improved efficacy when combined with chemotherapy in advanced NSCLC.<br /><br />The study included 42 patients with stage IIB-III NSCLC who received neoadjuvant treatment with tislelizumab and platinum-based doublet chemotherapy. The primary endpoint was treatment-related adverse events, which were mostly grade 1 or 2, with no grade 4 or 5 events observed. The most common adverse events were alopecia, rash, anemia, and increased ALT/AST levels. Grade 3 adverse events occurred in 11.9% of patients.<br /><br />The study also assessed the efficacy of the treatment, with 76.2% of patients undergoing surgical resection and 96.9% achieving R0 resection. The major pathological response rate was 59.5%, and the pathological complete response rate was 35.7%. Nodal downstaging was observed in 78.1% of patients.<br /><br />The results suggest that neoadjuvant treatment with tislelizumab plus chemotherapy can lead to a high major pathological response rate and manageable toxicity in patients with stage IIB-III NSCLC. Further analysis of predictive biomarkers for efficacy and safety is ongoing. The study provides promising evidence for the use of preoperative immunotherapy in the treatment of resectable NSCLC.

Asset Subtitle

Yao-Bin Lin

Meta Tag

Speaker Yao-Bin Lin

Topic Locally Advanced Non-small Cell Lung Cancer - Neoadjuvant and Adjuvant Therapy

Keywords

tislelizumab

chemotherapy

NSCLC

neoadjuvant treatment

adverse events

surgical resection

pathological response

toxicity

predictive biomarkers

immunotherapy